[1] WHO. Guidelines for the Treatment of Malaria[M]. Geneva; World Health Organization Copyright(c) World Health Organization 2015. [2] Ponticell C,Monron G.Hydroxychloroquine in systemic lupus erythematosus (SLE)[J].Expert opinion on drug safety,2017,16(3):411-419. [3] Wilke WS,Clough JD.Therapy for rheumatoid arthritis:combinations of disease-modifying drugs and new paradigms of treatment[J].Seminars in arthritis and rheumatism,1991,21(2 Suppl1):21-34. [4] 王华光,赵瑞,刘丽宏.硫酸羟氯喹致皮肤色素沉着1例并文献复习[J].临床药物治疗杂志,2017,15(9):77-79. [5] 张思. 系统性红斑狼疮患者长期口服羟氯喹引起纵向黑甲1例[C]//中国中西医结合学会皮肤性病专业委员会2017全国中西医结合皮肤性病学术年会论文汇编.中国中西医结合学会皮肤性病专业委员会,2017,157-158. [6] Lisi P,Assalve D,Hansel K.Phototoxic and photoallergic dermatitis caused by hydroxychloroquine[J].Contact Dermatitis,2004,50(4):255-256. [7] Tosios KI,Kalogirou EM,Sklavounou A.Drug-associated hyperpigmentation of the oral mucosa: report of four cases[J].Oral Surg Oral Med Oral Pathol Oral Radiol,2018,125(3):e54-e66. [8] Puri PK,Lountzis NI,Tyler W, et al.Hydroxychloroquine-induced hyperpigmentation: the staining pattern[J].J Cutan Pathol,2008,35(12):1134-1137. [9] 徐速. 氯喹引起的神经肌病[J].国外医学.皮肤病学分册,1987(1):41. [10] Fernandes MRN,Soares DBR,Thien CI, et al.Hydro-xychloroquine ototoxicity in a patient with systemic lupus erythe-matosus[J].Anais brasileiros de dermatologia,2018,93(3):469-470. [11] Das P,Rai A,Chopra AA, et al.Psychosis likely induced by hydroxychloroquine in a patient with chronic Q fever: a case report and clinically relevant review of pharmacology[J].Psychos-omatics,2014,55(4):409-413. [12] 王荪. 氯喹神经肌病[J].国外医学参考资料神经病学神经外科学分册,1978(4):200. [13] Seckin U,Ozoran K,Ikinciogullari A, et al.Hydroxychlo-roquine ototoxicity in a patient with rheumatoid arthritis[J].Rheumatology international,2000,19(5):203-204. [14] Marmor MF,Kellner U,Lai TY, et al.Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy(2016 Revision)[J].Ophthalmology,2016,123(6):1386-1394. [15] Furst DE.Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases[J].Lupus,1996,5(Suppl 1):11-15. [16] Hedner RT,Samulesson O,Wahrborg P, et al.Nabumetone:therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis[J].Drugs,2004,64(20):2315-2343. [17] Melles RB,Marmor MF.The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy[J].JAMA ophthalmology,2014,132(12):1453-1460. [18] Couturier A,Giocanti-Auregan A,Dupas B, et al.[Update on recommendations for screening for hydroxychloroquine retinopathy][J].Journal francais d'ophtalmologie,2017,40(9):793-800. [19] Saussine A,Loriot MA,Picard C, et al.[Chloroquine cardio-toxicity in long-term lupus therapy in two patients][J].Annales de dermatologie et de venereologie,2009,136(6-7):530-535. [20] Yogasundaram H,Hung W,Paterson ID, et al.Chloroquine-induced cardiomyopathy: a reversible cause of heart failure[J].ESC heart failure,2018,5(3):372-375. [21] Yogasundaram H,Putko BN,Tien J, et al.Hydroxychl-oroquine-induced cardiomyopathy: case report, pathophysiology,diagnosis, and treatment[J].The Canadian journal of cardiology,2014,30(12):1706-1715. [22] Kreger BE,Anderson KM,Kannel WB.Prevalence of intr-aventricular block in the general population: the Framingham Study[J].American heart journal,1989,117(4):903-910. [23] Cameron MC,Word AP,Dominguez A.Hydroxychloroqu-ine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus[J/OL].Dermatology online journal,2014, 20 (11)[2020-02-24].heep://pubmed.cn/2541.9748. [24] Murphy M,Carmichael AJ.Fatal toxic epidermal necrolysis associated with hydroxychloroquine[J].Clinical and experimental dermatology,2001,26(5):457-458. [25] Callaly EL,Fitzgerald O,Rogers S.Hydroxychloroquine-associated, photo-induced toxic epidermal necrolysis[J].Clinical and experimental dermatology,2008,33(5):572-574. [26] Ducharme J,Farinotti R.Clinical Pharmacokinetics and Metabolism of Chloroquine[J].Clinical pharmacokinetics,1996,31(4):257-274. |